Cytokinetics
CYTK
181 hedge funds and large institutions have $1.47B invested in Cytokinetics in 2020 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 86 increasing their positions, 36 reducing their positions, and 20 closing their positions.
139% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 36
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
24% more call options, than puts
Call options by funds: $62.7M | Put options by funds: $50.4M
15% more funds holding
Funds holding: 158 → 181 (+23)
8% more capital invested
Capital invested by funds: $1.36B → $1.47B (+$108M)
0.24% more ownership
Funds ownership: 97.37% → 97.6% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$77.7M |
| 2 |
RI
RTW Investments
New York
|
+$46.8M |
| 3 |
BlackRock
New York
|
+$32.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.9M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$24.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$78.9M |
| 2 |
Millennium Management
New York
|
-$12.7M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$11.8M |
| 4 |
Jennison Associates
New York
|
-$8.11M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$3.72M |
CYTK Hedge Fund Activity: Q3 2020 in Review
181 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2020, worth a combined $1.47B — up 7.9% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CYTK positions and 20 closed out — a net gain of 23 holders — while 86 added to existing stakes and 36 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $77.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $78.9M sold.
- 181 institutional investors held Cytokinetics (CYTK) as of Q3 2020, up from 158 in Q2 2020.
- Funds reported $1.47B of Cytokinetics stock for Q3 2020, up 7.9% quarter-over-quarter.
- 43 funds opened new Cytokinetics positions in Q3 2020 and 20 closed out, a net change of +23 holders.
- The largest Cytokinetics buyer in Q3 2020 was BVF Inc, an estimated $77.7M added.
- The largest Cytokinetics seller in Q3 2020 was Consonance Capital Management, an estimated $78.9M sold.
Based on aggregated 13F filings for Q3 2020.